| Schedule of sales, cost of goods sold and gross profit by segment |
For the three months ended June 30, 2026, the Company’s segment gross profit was comprised of the following (in thousands): | | | | | | | | | | | | | Women's Health | | | Cardiovascular | | | Total | Net sales | | $ | 1,283 | | $ | 1,144 | | $ | 2,427 | Cost of goods sold, excluding intangible asset amortization | | | 538 | | | 172 | | | 710 | Segment gross profit | | $ | 745 | | $ | 972 | | $ | 1,717 |
For the six months ended June 30, 2026, the Company’s segment gross profit was comprised of the following (in thousands): | | | | | | | | | | | | | Women's Health | | | Cardiovascular | | | Total | Net sales | | $ | 3,372 | | $ | 2,169 | | $ | 5,541 | Cost of goods sold, excluding intangible asset amortization | | | 1,428 | | | 324 | | | 1,752 | Segment gross profit | | $ | 1,944 | | $ | 1,845 | | $ | 3,789 |
For the three months ended June 30, 2025, the Company’s segment gross profit was comprised of the following (in thousands): | | | | | | | | | | | | | Women's Health | | | Cardiovascular | | | Total | Net sales | | $ | 2,011 | | $ | 736 | | $ | 2,747 | Cost of goods sold, excluding intangible asset amortization | | | 895 | | | 129 | | | 1,024 | Segment gross profit | | $ | 1,116 | | $ | 607 | | $ | 1,723 |
For the six months ended June 30, 2025, the Company’s segment gross profit was comprised of the following (in thousands) | | | | | | | | | | | | | Women's Health | | | Cardiovascular | | | Total | Net sales | | $ | 4,636 | | $ | 1,062 | | $ | 5,698 | Cost of goods sold, excluding intangible asset amortization | | | 2,068 | | | 253 | | | 2,321 | Segment gross profit | | $ | 2,568 | | $ | 809 | | $ | 3,377 |
|
| Reconciliation of segment gross profit to the consolidated loss before provision for income taxes |
The following table is a reconciliation of segment gross profit to the consolidated loss before provision for income taxes for the three and six months ended June 30, 2026 and 2025, (in thousands): | | | | | | | | | | | | | | | Three Months Ended | | Six Months Ended | | | June 30, | | June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | Segment gross profit | | $ | 1,717 | | $ | 1,723 | | $ | 3,789 | | $ | 3,377 | Adjustments: | | | | | | | | | | | | | Intangible asset amortization expense | | | (270) | | | (270) | | | (540) | | | (542) | Sales and marketing | | | (1,366) | | | (1,273) | | | (2,846) | | | (2,268) | General and administrative | | | (3,454) | | | (3,552) | | | (7,545) | | | (7,273) | Research and development | | | (2,527) | | | (989) | | | (4,500) | | | (1,860) | Litigation costs, net | | | (2,057) | | | (4,004) | | | (2,663) | | | (6,576) | Loss from operations | | | (7,957) | | | (8,365) | | | (14,305) | | | (15,142) | Interest income, net | | | (35) | | | (491) | | | (143) | | | (307) | (Gain) loss on revaluation of warrant liability | | | (226) | | | (2,233) | | | 1,429 | | | (7,420) | Other (income) expense, net | | | (58) | | | 1,442 | | | (129) | | | 1,547 | Loss before provision for income taxes | | $ | (7,638) | | $ | (7,083) | | $ | (15,462) | | $ | (8,962) |
|